Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.11.23	Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego (EN, Eli Lilly)
28.11.23	Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego (PR Newswire)
17.11.23	Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany (RTTNews)
17.11.23	Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany (EN, Eli Lilly)
17.11.23	Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany (PR Newswire)
17.11.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 (EN, Eli Lilly)
17.11.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 (PR Newswire)
15.11.23	Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma (RTTNews)
14.11.23	Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma (PR Newswire)
14.11.23	Lilly to Participate in Evercore ISI HealthCONx Conference (PR Newswire)
09.11.23	Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16 (RTTNews)
09.11.23	Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity (RTTNews)
08.11.23	Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma (PR Newswire)
08.11.23	FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems (PR Newswire)
02.11.23	Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting (PR Newswire)
02.11.23	Eli Lilly Cuts Annual Earnings Outlook Below View - Update (RTTNews)
02.11.23	Eli Lilly And Co. Q3 Earnings Summary (RTTNews)
02.11.23	Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity (PR Newswire)
01.11.23	Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease (PR Newswire)
01.11.23	Lilly Declares Fourth-Quarter 2023 Dividend (PR Newswire)
27.10.23	FDA Approves Lilly's Omvoh For Ulcerative Colitis Treatment (RTTNews)
27.10.23	FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
26.10.23	Lilly to Participate in UBS Biopharma Conference 2023 (PR Newswire)
21.10.23	Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and... (PR Newswire)
20.10.23	Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement (PR Newswire)
20.10.23	Eli Lilly Reports Five-year Outcomes From Pre-planned Analysis Of Phase 3 MonarchE Study (RTTNews)
20.10.23	Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer (PR Newswire)
20.10.23	Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years (PR Newswire)
16.10.23	Lilly's Tirzepatide Shows Addl 21.1% Weight Loss After 12 Weeks Of Intensive Lifestyle Intervention (RTTNews)
16.10.23	Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks (PR Newswire)
12.10.23	Lilly: Mirikizumab Phase 3 Trial In Adults With Crohn's Disease Meets Coprimary Endpoints (RTTNews)
12.10.23	Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial (PR Newswire)
06.10.23	Lilly Announces Details of Presentations at ESMO Congress 2023 (PR Newswire)
04.10.23	Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
04.10.23	Lilly Announces Leadership Transitions (PR Newswire)
03.10.23	Lilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre Market (RTTNews)
03.10.23	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies (PR Newswire)
02.10.23	Eli Lilly: FDA Issues CRL For Lebrikizumab BLA Related To Third-party Manufacturing Organization (RTTNews)
02.10.23	U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer (PR Newswire)
22.09.23	Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease (RTTNews)
22.09.23	US FDA approves Jardiance® for the treatment of adults with chronic kidney disease (PR Newswire)
20.09.23	Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale (RTTNews)
29.08.23	Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
22.08.23	Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint (RTTNews)
22.08.23	Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer (PR Newswire)
14.08.23	Eli Lilly Completes Acquisition Of Versanis Bio (RTTNews)
14.08.23	Lilly Completes Acquisition of Versanis Bio (PR Newswire)
14.08.23	Eli Lilly Concludes Acquisition Of Sigilon Therapeutics (RTTNews)
14.08.23	Lilly Completes Acquisition of Sigilon Therapeutics (PR Newswire)
09.08.23	Lilly Completes Acquisition of DICE Therapeutics (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:06		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
15:58		Anleger in Frankfurt halten sich zurück: LUS-DAX liegt nachmittags im Minus
15:58		Donnerstagshandel in Europa: Euro STOXX 50 zeigt sich nachmittags schwächer

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone

17:56

Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an

16:06

Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa